Latest Leadership News

Murray Cod Australia (ASX:MCA) has launched the retail tranche of its fully underwritten $18.6 million entitlement offer at a 43% discount, aiming to convert its record 3,700-tonne biomass into cash and expand processing capacity.

QBE Insurance Group kicked off 2026 with robust premium growth and solid underwriting, maintaining its full-year guidance amid geopolitical uncertainty and evolving risks.

Neometals is pivoting towards gold production with a funded JV at its Barrambie Ironclad deposit, while simultaneously progressing a substantial lithium-potash brine project in Utah.

REA Group delivered robust Q3 FY26 results, driven by double-digit revenue growth in Australia and record engagement on realestate.com.au, while lowering its cost growth guidance for FY26.

Vectus Biosystems appoints Dr Tara Speranza as CEO and CTO to accelerate development of lead fibrosis drug VB0004 with performance-linked incentives.

Promisia Healthcare’s portfolio value jumps 17.1% to $107.2 million, driven by improved occupancy and operational efficiencies across all sites.

Proteomics International Laboratories (ASX:PIQ) has denied any undisclosed material information following a sharp share price drop and heightened trading activity, pointing instead to recent strategic updates and organisational changes.

Tali Resources has raised $3 million through a discounted share placement to bankroll a multi-phase drilling campaign at its West Arunta Project, aiming to capitalise on recent geophysical advances.

Boom Logistics has upgraded its FY26 earnings guidance, anticipating a 31% rise in statutory EPS, backed by $7 million in new contracts across energy and mining sectors.

ARN Media reported a 10% revenue decline in FY25 but accelerated digital growth and cost savings, while defending ongoing legal disputes with former talent.

Zip Co’s April update highlights robust US and ANZ market expansion, with total transaction volume surging and credit losses forecast below 1.75%. The company reconfirms FY26 guidance, underpinned by AI-driven underwriting and new subscription offerings.

Arovella Therapeutics has named Dr Nicole Van Der Weerden as acting CEO following Dr Michael Baker’s departure, positioning her to steer the company through the critical phase I trial of its CAR-iNKT therapy ALA-101.